Closed · PA-07-309 · CFDA 93.279 · Discretionary
Drug Abuse Aspects of HIV/AIDS (R21)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- -
- Close date
- -
- Expected awards
The verdict
Drug Abuse Aspects of HIV/AIDS (R21) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 93.279
- CFDA program
Opportunity snapshot. This Grants.gov announcement - Drug Abuse Aspects of HIV/AIDS (R21) - is cataloged under number PA-07-309 and tied to CFDA assistance listing 93.279, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on January 17, 2007 and last updated on December 5, 2008. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity is closed. Monitoring the parent program page is the most reliable way to catch re-announcements in the next funding cycle. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
Not specified
Multiple Receipt Dates - See Link to Full Announcement for details.
Posted
January 17, 2007
Instrument
Grant
Description
Purpose. This Funding Opportunity Announcement (FOA) using the Exploratory/Developmental Grant (R21) encourages drug abuse research that addresses the changing dynamics of the HIV/AIDS epidemic in the U.S., such as the increasing over-representation of minorities and women among new AIDS cases and role of heterosexual sex as a transmission route. Studies are needed to develop novel preventive interventions that more effectively address the evolving epidemic. Internationally, studies are needed on how to translate and adapt interventions that have proved effective in the U.S. to other communities and international settings, and to learn from other conditions and cultures to inform our understanding of the causes, consequences, and differences in HIV-associated risks, morbidity, and mortality in diverse populations. The Exploratory/ Developmental Grant (R21) is intended for early and conceptual research development, for example to assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Such studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of innovative techniques, agents, methodologies, models or applications that could have major impact on a field of biomedical, behavioral, or clinical research. Applications for R21 awards should be for projects distinct from those supported through the traditional R01 mechanism. Long-term projects, or projects designed to increase knowledge in a well-established area, will not be considered for R21 awards. Applications submitted under the R21 mechanism should be exploratory and novel, and seek to break new ground or extend previous discoveries toward new directions or applications.
Eligibility
Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Drug Abuse Research Programs
National Institutes of Health
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |